Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
25000 participants
OBSERVATIONAL
2006-01-01
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Achievement of the target LDL-C at 1-year follow-up LDL-C \<70 mg / dl in the group of very high-risk and LDL-C \<100 mg / dL in high-risk patients
2. Assessment of the lipid profile of the severity of coronary artery disease in patients undergoing invasive diagnosis of coronary artery disease
3. Evaluation of trends in the treatment of lipid-lowering in patients in different years
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study population is formed by all-comer patients hospitalized in cardiology wards and intensive cardiac care units with a diagnosis of coronary disease, both stable angina, and acute coronary syndromes (ACS). For the purpose of this study hyperlipidaemia is defined in accordance with European Society of Cardiology guidelines.
Complete patient demographics; medical history, complete hospitalization data (diagnostic and therapeutic), in-hospital and out-hospital results are collected in an electronic form by the attending physician. The patients are under constant follow-up for all cause mortality and major adverse events.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Silesian Centre for Heart Diseases
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mariusz Gasior
Prof. of Medicine, Head of 3rd Department of Cardiology, SMDZ in Zabrze, Medical University of Silesia, Katowice, Poland
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mariusz Gasior, prof.MD,PhD
Role: PRINCIPAL_INVESTIGATOR
3rd Department of Cardiology, SMDZ in Zabrze, Medical University of Silesia, Katowice, Poland
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Silesian Center for Heart Diseases
Zabrze, Upper Silesia, Poland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Krzysztof Dyrbus
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Dyrbus K, Osadnik T, Desperak P, Desperak A, Gasior M, Banach M. Evaluation of dyslipidaemia and the impact of hypolipidemic therapy on prognosis in high and very high risk patients through the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) Registry. Pharmacol Res. 2018 Jun;132:204-210. doi: 10.1016/j.phrs.2017.12.015. Epub 2017 Dec 16.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
III KOK 01/2017
Identifier Type: -
Identifier Source: org_study_id